Table 3.

MINDACT: Analysis by age.

	Luminal—C-high/G-low 40–50 years (n= 399)		Luminal—C-high/G-low >50 years (n = 865)
	5-year DMFS (%)	Difference (%)	5-year DMFS (%)	Difference (%)
CT	96.2	+ 3.6←	95.2	-0.2
No CT	92.6		95.4

A total of 1358 patients with Luminal (HR+/HER2−) patients from MINDACT had C-high/G-low risk for recurrence. There were too few patients (n = 53) and events in the <40 age group for analysis. Results for the 40–50, and >50 age groups are shown in the table; the groups were well matched for tumor size (2.2 cm, both groups), nodal status (N0, >50% both groups), and grade (~65% Grade 2 both groups).⁹